Long Duration Stimulant Treatment Study of Preschoolers With ADHD-Feasibility Study
|ClinicalTrials.gov Identifier: NCT00257725|
Recruitment Status : Completed
First Posted : November 23, 2005
Last Update Posted : February 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|Attention Deficit Disorder With Hyperactivity||Drug: Ritalin LA™||Phase 4|
This is a single site, open-label, four-week feasibility study of long-duration beaded methylphenidate (B-MPH), also known as Ritalin LA™. B-MPH is a FDA-approved medication for children 6 years and older with attention-deficit/hyperactivity disorder (ADHD), but there are no studies of its use in preschoolers. This study will evaluate the safety and effectiveness of B-MPH for ADHD treatment in 4-to-5-year old children.
Total study duration is approximately 5 weeks. It includes a screening evaluation and 4 weeks of B-MPH treatment with doses ranging from 10 to 30 mg (based on the individual tolerability and efficacy). The study doctor will conduct parent-training sessions during the treatment visits.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||March 2005|
|Actual Primary Completion Date :||March 2008|
|Actual Study Completion Date :||March 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257725
|United States, New York|
|New York State Psychiatric Insitute|
|New York, New York, United States, 10032|
|Principal Investigator:||Laurence L Greenhill, MD||New York State Psychiatric Insitute|